SRPT Q3 2024 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$467M+40.8% YoY

Gross Profit

$375M80.4% margin

Operating Income

$22M4.8% margin

Net Income

$34M7.2% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

+28.7%

Cash Flow

Operating Cash Flow

-$71M

Free Cash Flow

-$108M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$3.6B

Total Liabilities

$2.4B

Stockholders' Equity

$1.2B

Cash & Equivalents

$198M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$467M	$332M	+40.8%
Gross Profit	$375M	$295M	+27.4%
Operating Income	$22M	-$21M	+206.5%
Net Income	$34M	-$41M	+182.1%

Geographic Segments

UNITED STATES

$211M85%

Rest of World

$38M15%